Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status
Clinical Trial Phase Therapies Title Recruitment Status
NCT02613650 Phase I Binimetinib + Fluorouracil + Irinotecan + Leucovorin A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers Recruiting
NCT03992456 Phase II Panitumumab Regorafenib Trifluridine-tipiracil hydrochloride Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer Recruiting
NCT02906059 Phase I Adavosertib + Irinotecan Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer Recruiting
NCT03442569 Phase II Ipilimumab + Nivolumab + Panitumumab PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC Active, not recruiting
NCT03365882 Phase II Cetuximab + Irinotecan Pertuzumab + Trastuzumab S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery Recruiting
NCT03446157 Phase II Cetuximab + Palbociclib Palbociclib and Cetuximab in Metastatic Colorectal Cancer Recruiting
NCT03592641 Phase II Savolitinib Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer Recruiting
NCT03981614 Phase II Trifluridine-tipiracil hydrochloride Binimetinib + Palbociclib Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer Recruiting
NCT03087071 Phase II Panitumumab Panitumumab + Trametinib Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer Recruiting
NCT04495621 Phase Ib/II Cetuximab + CH5132799 MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01) (C-PRECISE-01) Recruiting
NCT02573220 Phase I Cetuximab + Fluorouracil + Irinotecan + Leucovorin Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer Withdrawn
NCT01814501 Phase II Fluorouracil + Irinotecan + Leucovorin Panitumumab Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab Active, not recruiting
NCT04429542 Phase I BCA101 BCA101 + Pembrolizumab Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors Recruiting
NCT01937715 Phase II Bevacizumab Gedatolisib Fluorouracil + Irinotecan + Leucovorin A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer Terminated
NCT04117945 Phase II Regorafenib Irinotecan + Panitumumab Panitumumab Cetuximab + Irinotecan Cetuximab Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer Recruiting
NCT03457896 Phase II Cetuximab + Neratinib Neratinib + Trastuzumab Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status Recruiting
NCT02205398 Phase Ib/II Capmatinib + Cetuximab Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy Terminated
NCT03300609 Phase III Capecitabine Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab Fluorouracil + Leucovorin + Panitumumab 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab Terminated
NCT01312857 Phase II Panitumumab Fluorouracil + Irinotecan + Leucovorin Floxuridine Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer Active, not recruiting
NCT02508077 Phase II Fluorouracil + Irinotecan + Leucovorin Panitumumab FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Terminated
NCT02318901 Phase Ib/II Ado-trastuzumab emtansine + Pembrolizumab Pembrolizumab + Trastuzumab Cetuximab + Pembrolizumab Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer Terminated
NCT04169347 Phase II Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Panitumumab FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer Recruiting
NCT03384940 Phase II Trastuzumab deruxtecan DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01) Active, not recruiting
NCT03668431 Phase II Dabrafenib + Spartalizumab + Trametinib Dabrafenib + Trametinib + PDR001 In Colorectal Cancer Recruiting
NCT02568046 Phase Ib/II Fluorouracil + Irinotecan + Leucovorin + SYM004 Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients Terminated
NCT01960023 Phase Ib/II Cetuximab + Neratinib Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer Withdrawn
NCT02713373 Phase Ib/II Cetuximab + Pembrolizumab Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery Active, not recruiting
NCT02599324 Phase Ib/II Cetuximab + Ibrutinib Ibrutinib + Paclitaxel Everolimus + Ibrutinib Docetaxel + Ibrutinib A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors Recruiting
NCT02785068 Phase I Fluorouracil + Irinotecan + Leucovorin + MM-151 Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer Withdrawn
NCT03069950 Phase II Dexamethasone + Floxuridine + Fluorouracil + Irinotecan + Leucovorin + Panitumumab Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver Withdrawn
NCT03580382 Phase Ib/II CDX-3379 + Trametinib Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma Terminated
NCT02224781 Phase III Ipilimumab + Nivolumab Dabrafenib + Trametinib Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma Recruiting
NCT02140840 Phase II Trametinib A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib Withdrawn
NCT03698994 Phase II Ulixertinib Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Recruiting
NCT03043313 Phase II Trastuzumab + Tucatinib Tucatinib Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer Recruiting
NCT02022982 Phase Ib/II Palbociclib + PD-0325901 PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors Active, not recruiting
NCT02292758 Phase II Bevacizumab + Cetuximab + Irinotecan Cetuximab + Irinotecan Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in KRAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer Completed
NCT01885195 Phase II Binimetinib MEK162 for Patients With RAS/RAF/MEK Activated Tumors Completed
NCT01915602 Phase II Refametinib + Sorafenib Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC) Completed
NCT03415126 Phase I ASN007 A Study of ASN007 in Patients With Advanced Solid Tumors Completed
NCT03213691 Phase II Selumetinib Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Active, not recruiting
NCT02974725 Phase I LXH 254 + Ribociclib LXH 254 + Trametinib LTT462 + LXH 254 A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma Recruiting
NCT01781429 Phase Ib/II Ulixertinib Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies Completed
NCT01306045 Phase II Erlotinib Lapatinib MK2206 Sunitinib Selumetinib Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies Active, not recruiting
NCT03732703 Phase Ib/II Dexamethasone + Enasidenib + Ixazomib + Pomalidomide Cobimetinib + Dexamethasone + Ixazomib + Pomalidomide Dexamethasone + Erdafitinib + Ixazomib + Pomalidomide Dexamethasone + Ixazomib + Pomalidomide + Venetoclax Abemaciclib + Dexamethasone + Ixazomib + Pomalidomide Daratumumab + Dexamethasone + Ixazomib + Pomalidomide Myeloma-Developing Regimens Using Genomics (MyDRUG) (MyDRUG) Recruiting
NCT01449058 Phase Ib/II Alpelisib + Binimetinib A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors Completed
NCT04417621 Phase II LTT462 + LXH 254 Trametinib Ribociclib Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma Recruiting
NCT04515394 Phase II Cetuximab + Tepotinib Study of Tepotinib Combined With Cetuximab in Participants Left-Sided Metastatic Colorectal Cancer (mCRC) Acquired Resistance Due to Mesenchymal Epithelial Transition (MET) Amplification Not yet recruiting
NCT01781572 Phase Ib/II Binimetinib + Ribociclib A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma Completed
NCT04145297 Phase I Hydroxychloroquine + Ulixertinib Ulixertinib (BVD-523) and Hydroxychloroquine in Patients w Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas (UTAH) Recruiting
NCT02965417 Phase II SYM004 Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients Withdrawn
NCT03037385 Phase Ib/II Pralsetinib Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW) Recruiting
NCT03377361 Phase Ib/II Ipilimumab + Nivolumab Ipilimumab + Nivolumab + Trametinib An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Patients With Previously Treated Cancer of the Colon or Rectum That Has Spread Active, not recruiting
NCT01693068 Phase II Dacarbazine Pimasertib Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma Completed
NCT03637491 Phase II Avelumab + Binimetinib + Talazoparib Avelumab + Binimetinib A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors Recruiting
NCT02723006 Phase I MLN2480 + Nivolumab MLN1202 + Nivolumab Ipilimumab + Nivolumab + Vedolizumab Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma Terminated
NCT04211337 Phase III Vandetanib Cabozantinib Selpercatinib A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531) Recruiting
NCT03919292 Phase Ib/II Divalproex sodium + Neratinib Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca Recruiting
NCT01737502 Phase Ib/II Auranofin + Sirolimus Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer Recruiting
NCT03162627 Phase I Olaparib + Selumetinib Selumetinib and Olaparib in Solid Tumors Recruiting
NCT03317119 Phase I Trametinib + Trifluridine-tipiracil hydrochloride Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery Active, not recruiting
NCT02630420 Phase I Cetuximab + Savolitinib Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer Withdrawn
NCT03181100 Phase II Atezolizumab + Cobimetinib Atezolizumab + Bevacizumab Atezolizumab + Nab-paclitaxel Atezolizumab + Cobimetinib + Vemurafenib Atezolizumab + Paclitaxel Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer Recruiting
NCT03983993 Phase II Niraparib + Panitumumab Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer (NIPAVect) Recruiting
NCT02648490 Phase I Acetaminophen + Dexamethasone + Diphenhydramine + Ondansetron HLX07 An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers Completed
NCT03613532 Phase I Busulfan + Fludarabine + Venetoclax Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN Recruiting
NCT04109456 Phase I BI 853520 + Cobimetinib BI 853520 IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma Recruiting
NCT02857270 Phase I LY3214996 Gemcitabine + LY3214996 + Nab-paclitaxel LY3214996 + Midazolam Abemaciclib + LY3214996 A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer Recruiting
NCT03051035 Phase I KO-947 First-in-Human Study of KO-947 in Non-Hematological Malignancies Active, not recruiting
NCT02285439 Phase Ib/II Binimetinib Phase I/II Study of MEK162 for Children With Ras/Raf Pathway Activated Tumors Recruiting
NCT02089230 Phase Ib/II Binimetinib MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy Completed
NCT01907815 Phase II Trametinib + Uprosertib Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia Terminated
NCT03190915 Phase II Trametinib Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia Recruiting
NCT02607813 Phase I LXH 254 + Spartalizumab LXH 254 Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations Recruiting
NCT02747537 Phase II Irinotecan + Sorafenib Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan Withdrawn
NCT02610361 Phase I BGB-283 Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors Completed
NCT03913026 Phase II ECT-001 cord blood cells Mycophenolate mofetil Tacrolimus Cyclophosphamide + Fludarabine Cyclophosphamide + Fludarabine + Thiotepa UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia Recruiting
NCT02296242 Phase Ib/II Ulixertinib Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes Completed
NCT03091257 Phase I Dabrafenib + Trametinib Dabrafenib Trametinib A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma Recruiting
NCT02296112 Phase II Trametinib Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations Active, not recruiting
NCT01763164 Phase III Dacarbazine Binimetinib Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Completed
NCT01740648 Phase I Fluorouracil + Trametinib Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer Active, not recruiting
NCT02049801 Phase I Binimetinib + Cytarabine + Idarubicin MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Terminated
NCT02465060 Phase II Erdafitinib Copanlisib Trametinib Crizotinib Sunitinib Sapanisertib Nivolumab AZD4547 Dasatinib Pertuzumab + Trastuzumab Dabrafenib + Trametinib Binimetinib Adavosertib Osimertinib Palbociclib Afatinib Capivasertib Defactinib GSK2636771 Vismodegib Ado-trastuzumab emtansine Larotrectinib Taselisib Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Recruiting
NCT03745326 Phase Ib/II Aldesleukin + anti-KRAS G12D mTCR cells + Cyclophosphamide + Fludarabine Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients Recruiting
NCT03190941 Phase Ib/II Cyclophosphamide anti-KRAS G12V mTCR cells Fludarabine Aldesleukin Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients Recruiting
NCT04487106 Phase II Azacitidine + Trametinib + Venetoclax Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome Recruiting
NCT03310541 Phase I Capivasertib Capivasertib + Enzalutamide Capivasertib + Fulvestrant AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations Active, not recruiting
NCT02587650 Phase II Ceritinib Capmatinib Regorafenib Entrectinib Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma Terminated
NCT02097225 Phase I Dabrafenib + Onalespib + Trametinib Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Active, not recruiting
NCT03429803 Phase Ib/II MLN2480 TAK-580 In Gliomas and Other Tumors Recruiting
NCT04418167 Phase I JSI-1187 Dabrafenib + JSI-1187 JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations Recruiting
NCT02257424 Phase Ib/II Dabrafenib + Hydroxychloroquine + Trametinib Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma (BAMM) Active, not recruiting
NCT03973918 Phase II Binimetinib + Encorafenib Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG (BRAF) Recruiting
NCT03114319 Phase I TNO155 Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors Recruiting
NCT03919071 Phase II Dabrafenib + Trametinib Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma Recruiting
NCT02974803 Phase II Dabrafenib + Trametinib Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases Active, not recruiting
NCT04249843 Phase I BGB3245 Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors Recruiting